



## Case Studies Submission Guidelines

- Participants are encouraged to submit medical and surgical case studies. Case studies can be submitted from **19 February 2018** until ~~16 July 2018~~ **deadline POSTPONED to JULY 30<sup>TH</sup>, 2018!**

The Scientific Committee will review and select **up to four** of the submitted cases for presentation. Selected submissions will be notified by **27 August 2018**.

Accepted cases will be presented by the authors and discussed during the **\*Retinamour Clinical Case session** with an international expert panel.

### **\*Retinamour: Study Cases Discussion**

(1 case in 10 minutes -5 minutes presentation (max 4 slides) + 5 minutes discussion)

- A call is launched for the presentation of unusual or representative clinical cases on retinal or macular disease.
- The scientific committee will make a selection of max 4 cases among the cases presented.
- The selected speaker (one of the attendants whose clinical case was chosen) will present it
- the chairs will rapidly comment the case with the speaker during the presentation and at the end of it the audience may pose questions.

### **Eligible case studies should, but are not restricted to, focus on:**

- Interesting diagnosis and/or treatment
- Controversial management
- Interesting follow-up period

### **Format (submit the Abstract of your Case Study and 3-4 slides)**

- Abstracts should be submitted in English.
- Abstracts are limited **to 300 words** (excluding title, sub-titles and acknowledgements) therefore, it is important to plan, review and edit your abstract for clarity and concision.
- Please provide a minimum of 2 and a maximum of 5 specific keywords for scheduling and indexing purposes.
- Each abstract should have a brief descriptive title of 20 words maximum. Trademarks are not allowed in the abstract title.
- Illustrations are not accepted
- The following structure should be followed:
  - Introduction/Background
  - Methods
  - Results
  - Conclusions
  - Acknowledgements  
(Please list all sources of funding of the work described and other acknowledgements)
- Generic names must be used for all references to pharmaceutical products
- Please spell check your abstract prior to submission

- Please submit a maximum 4 slides to be presented in 5 minutes on retinal diseases medical/surgical cases.

### **File types: PowerPoint 2007/2010/2013 (i.e. pptx file)**

- After submitting your abstract, you will receive an e-mail **confirmation** (please make sure to state your correct e-mail address). Should you wish to make **corrections** to an abstract already submitted or if you wish to submit other abstracts later, you may use your personal access codes (until the deadline of 16 July 2018).



### Authors

- Author names and institutions must be declared. You will be asked to enter the name(s) of the author(s) and their institution(s), when submitting your abstract online.
- Abstracts should be submitted by first authors who vouch for the standards of research conduct and approval of co-authors for submission.
- First authors will present or nominate one of the authoring team to present the abstract if selected for presentation.
- Abstracts will be reviewed by the Review Committee and notice of abstract acceptance or rejection will be e-mailed to the submitting author **by 27 August 2018**.

### Submission Notification

- After submitting your case study, you will receive an e-mail confirmation (please make sure to state your correct e-mail address). Should you wish to make corrections to a case study already submitted or if you wish to submit other case studies later, you may use your personal access codes.
- Corrections to case studies can only be made up to the case study submission deadline of **16 July 2018**.

### Registration

To be eligible for a case study presentation **authors receiving a case study acceptance notification must register and make full payment UNTIL 8 september 2018** or advise us of withdrawal by this date.

### Contacts

For further information please contact [congress.retina@esaso.org](mailto:congress.retina@esaso.org)